Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Zhaoming Xiong

Donghong Amy Gao

Daniel R Goldberg

Neil Moss

Derek Cogan

Ming-Hong Hao

Alexander Heim-Riether

Lifen Wu

Matthew Russell Netherton

Ronald A Aungst, Jr

Abdelhakim Hammach

Lana Louise Smith Keenan

Victor Marc Kamhi

Kevin Chungeng Qian

Pier Francesco Cirillo

Robert Owen Hughes

Alan David Swinamer

Michael Jason Burke

Jiang-Ping Wu

Qiang Zhang

Xiang Li

Steven Richard Brunette

Craig Andrew Miller

Ingo Andreas Mugge

Joerg Bentzien

Mark Stephen Ralph

Philip Dean Ramsden

Yang Yu

Amy L Davis

Neil Alexander Farrow

Eugene R Hickey

Weimin Liu

Michael Robert Turner

Dieter Wiedenmayer

Todd Bosanac

Robert Sibley

Rene Marc Lemieux

Christopher Ronald Sarko

Roger John Snow

Keith R Hornberger

Zhonghua Zhang

Zhidong Chen

Peter Allen Nemoto

Bernd Wellenzohn

Maolin Yu

John Lord

Asitha Abeywardane

Michael Balestra

Matt Aaron Tschantz

Fariba Soleymanzadeh

Wang Mao

Bryan Patrick McKibben

Xin Guo

Shuang Liang

Steven John Taylor

Ji Wang

Sabine K Schlyer

Jennifer Burke

Darren Todd Disalvo

Jennifer A Kowalski

Jörg Martin Bentzien

Gregory Paul Roth

Johanna Csengery

John A Westbrook

Joshua Courtney Horan

Hui Yu

Kenneth Michael Meyers

Michael David Lawlor

David Charles Thompson

Yu Yang

Kaka Dey

Antonio Jose Del Moral Barbosa, Jr

John Edward Mangette

Bennett Farmer

Joerg Martin Bentzien

Bryan Mckibben

Donghong A Gao

Antonio Jose Del Moral Barbosa

The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR&#x3b3; and the treatment of diseases related to the modulation of ROR&#x3b3;. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them. 

Compounds as modulators of ROR gamma

The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use. 

Isoquinolones as BTK inhibitors

The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR&#x3b3; and the treatment of diseases related to the modulation of ROR&#x3b3;. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them. 

Pteridine derivatives as modulators of ROR gamma

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R, Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

Aldosterone synthase inhibitors

Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I. 

Heteroaryl substituted indole compounds useful as MMP-13 inhibitors

Disclosed are Cathepsin-S reversible inhibitor compounds of the formula (I) which are useful in the treatment of autoimmune and other diseases. Also disclosed are pharmaceutical compositions containing the same, and methods of making and using the same. 

Heteroaryl nitrile compounds useful as inhibitors of Cathepsin-S

Disclosed are compounds and compositions of the formula (I) as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula (I). 

Heteroaryl diamide compounds useful as MMP-13 inhibitors

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides

The invention relates to a compound of formula (I): or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein Rto R, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various diseases and disorders in a patient. The invention also relates to processes for preparing the compounds of formula (I) and intermediates useful in these processes.

CCR10 antagonists

The application relates to compounds of formula Ia and analogues thereof wherein Rto Rand X are as defined herein. The invention also relates to the use of the compounds of formula Ia as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.

Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors

Disclosed are compounds of formula (I) which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Cytokine inhibitors

Disclosed are amide compounds of formula (I): wherein Ar, Q, Y and R-Rof formula (I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases

Disclosed are compounds of formula (I) Where Ar, X, Y, Q, W, R, R, R, Rand Rare defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. The compounds are also useful for treating diseases or conditions related to oncology and anticoagulant or fibrinolytic therapy. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Growing community of inventors

Danbury, CT, United States of America

Zhaoming Xiong